Bayer Healthcare and Johnson & Johnson’s Janssen Pharmaceuticals subsidiary currently face nearly 90 product liability lawsuits over their new-generation coagulant, Xarelto. Late in 2014, the U.S. Judicial Panel on Multidistrict Litigation (MDL) announced that all nationwide Xarelto lawsuits filed in federal courts would be consolidated in the Eastern District of Louisiana before U.S. District Judge Eldon E. Fallon. Experts estimate that eventually several thousand cases will be transferred into the MDL.
An MDL typically streamlines the litigation process, helps avoid repetitive discovery and conflicting pre-trial motions, and allow bellwether trials to be set to determine the strength of the plaintiffs’ claims.
What is Xarelto?
Xarelto was developed by Bayer and Janssen Pharmaceuticals in 2011 as a new generation anticoagulant meant to be a superior alternative to Coumadin (warfarin) in terms of better prevention of strokes and non-central nervous system embolism and the absence of a requirement for regular blood monitoring, making use more convenient.
Although all blood thinners, including Xarelto and Coumadin, have side effects and increase the risk of bleeding problems, Xarelto has been associated with a high number of adverse reports involving injuries associated with uncontrollable bleeding. While the effects of warfarin can be quickly reversed in case of an emergency through the use of vitamin K and blood transfusions, there is no approved antidote available for those using Xarelto, and side effects from the drug have resulted in catastrophic outcomes when doctors were unable to control the bleeding.
All the Xarelto lawsuits make basically the same allegations: drug manufacturers failed to warn consumers and medical professionals about the potentially dangerous side effects of Xarelto, which include uncontrollable bleeding, the need for blood transfusions, and death in severe cases. According to court documents, severe injuries and deaths could have been avoided had the pharmaceutical companies not provided misleading information about the blood monitoring, and if stronger warnings had been issued concerning the lack of a reversal agent or antidote.
If you or a loved one has suffered serious, uncontrollable bleeding while on Xarelto, you should speak with Childers, Schlueter & Smith today about seeking compensation. It may be the only way to alleviate the financial hardship that has been placed upon you.
Consultations are free and without obligation.